Baricitinib (Olumiant) is indicated for the treatment of rheumatoid arthritis and COVID-19 in hospitalized adults.
Matthew Gall
Advertisement
Articles by Matthew Gall
In clinical trials, Xiidra was found to improve eye dryness scores significantly compared with placebo.
The FDA approved daridorexant in January 2022 to treat insomnia after it showed improvements in changes in latency to persistent sleep and wake after sleep onset.
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
Effectively Managing Immunizations in the Long-Term Care Setting
5
